Real world data for rare diseases research: The beginner’s guide to registries

References

• Food and Drug Administration. Framework for FDA’s real-world evidence program. U.S. Food And Drug Administration, Dec 2018. [cited 2022 Dec 20]; Available from: https://www.fda.gov/media/120060/download.
   Google Scholar
• The European Network for Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on methodological standards in pharmacoepidemiology. [cited 2022 Dec 19]; Available from: https://www.encepp.eu/standards_and_guidances/methodologicalGuide15_6.shtml.
   Google Scholar
• Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther. 2019 Jul;106(1):36–39. doi: 10.1002/cpt.1426
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clinical Epidemiol. 2005;58(4):323–337. doi: 10.1016/j.jclinepi.2004.10.012
   PubMed Web of Science ®Google Scholar
• TCC MA, Kaplowitz H. Role of epidemiological data within the drug development lifecycle: a chronic migraine case study. In: Lunet N, editor. Epidemiology - Current Perspectives on Research and Practice: IntechOpen. 2012. doi: 10.5772/32343
   Google Scholar
• [US DeparTment of Health and Human Services, Food and Drug Administration, 21 CFR Part 316, [Docket No. FDA–2011–N–0583] RIN 0910–AG72. Orphan Drug Regulations. Available from: https://www.govinfo.gov/content/pkg/FR-2013-06-12/pdf/2013-13930.pdf;
   Google Scholar
• European Medicines Agency (EMA). Procedural advice for orphan medicinal product designation; 13 Oct 2022, EMA/420706/2018 Rev 121. [cited 2022 Dec 20]; Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-orphan-medicinal-product-designation-guidance-sponsors_en.pdf.
   Google Scholar
• Richter T, Nestler-Parr S, Babela R, et al. Rare disease terminology and definitions-a systematic global review: report of the ISPOR Rare Disease Special Interest Group. Value Health. 2015;18:906–914.
   PubMed Web of Science ®Google Scholar
• de la Paz MP, Taruscio D, Groft SC, Eds. Rare diseases epidemiology: update and overview, Chapter 1. Springer; 2017.
   Google Scholar
• Maier WC, Christensen RA, Anderson P. Post-approval studies for rare disease treatments and orphan drugs. Adv Exp Med Biol. 2017;1031:197–205.
   PubMed Web of Science ®Google Scholar
• Bouvy JC, Blake K, Slattery J, et al. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013. Pharmacoepidemiol Drug Saf. 2017 Dec;26(12):1442–1450. Epub 2017 Mar 26. doi: 10.1002/pds.4196
   PubMed Web of Science ®Google Scholar
• Gliklich RE, Dreyer NA, Leavy MB, eds. Registries for evaluating patient outcomes: a user’s guide. Rockville MD: Agency for Healthcare Research and Quality (US); 2014 Apr
   Google Scholar
• Initiative for patient registries. EMA/176050/2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2015/10/WC500195576.pdf.
   Google Scholar
• Lochmüller H, Torrent i Farnell J, Le Cam Y, et al. The international rare diseases research consortium: policies and guidelines to maximize impact. Eur J Hum Genet. 2017;25:1293–1302. doi: 10.1038/s41431-017-0008-z
   PubMed Web of Science ®Google Scholar
• Taruscio D, Kodra Y, Ferrari G, et al. The Italian national rare diseases registry. Blood Transfus. 2014 Apr;12(Suppl 3):s606–13. PMID: 24922301; PMCID: PMC4044798. doi: 10.2450/2014.0064-14s
   PubMedGoogle Scholar
• European Medicines Agency (EMA). Guideline on registry-based studies. Oct 2021. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-registry-based-studies_en.pdf
   Google Scholar
• Montilla S, Xoxi E, Russo P, et al. Monitoring registries at Italian medicines agency: fostering access, guaranteeing sustainability. Int J Technol Assess Health Care. 2015 Jan;31(4):210–213.
   PubMed Web of Science ®Google Scholar
• Hollak CEM, Sirrs S, van den Berg S, et al. Registries for orphan drugs: generating evidence or marketing tools? Orphanet J Rare Dis. 2020 Sep 3;15(1):235. PMID: 32883346; PMCID: PMC7469301. doi: 10.1186/s13023-020-01519-0
   PubMed Web of Science ®Google Scholar
• Crisafulli S, Sultana J, Ingrasciotta Y, et al. Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study. Expert Opin Drug Saf. 2019 Jun;18(6):497–509. doi: 10.1080/14740338.2019.1614165.
   PubMed Web of Science ®Google Scholar
• Cahan EM, Frick SL. Orthopaedic phenotyping of NGLY1 deficiency using an international, family-led disease registry. Orphanet J Rare Dis. 2019;14(1). doi: https://doi.org/10.1186/S13023-019-1131-4
   PubMedGoogle Scholar
• Stanclift CR, Dwight SS, Lee K, et al. NGLY1 deficiency: estimated incidence, clinical features, and genotypic spectrum from the NGLY1 registry. Orphanet J Rare Dis. 2022 Dec 17;17(1):440. doi: 10.1186/s13023-022-02592-3
   PubMed Web of Science ®Google Scholar
• Borbath I, Garcia-Carbonero R, Bikmukhametov D, et al. The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms. Eur J Cancer. 2022 Jun;168:80–90. Epub 2022 Apr 23. PMID: 35472579. doi: 10.1016/j.ejca.2022.03.007
   PubMed Web of Science ®Google Scholar
• Bolton SC, Soran V, Marfa MP, et al. Clinical disease characteristics of patients with Niemann-pick disease type C: findings from the International Niemann-Pick Disease Registry (INPDR). Orphanet J Rare Dis. 2022 Feb 14;17(1):51. PMID: 35164809; PMCID: PMC8842861. doi: 10.1186/s13023-022-02200-4
   PubMed Web of Science ®Google Scholar
• Jonker CJ, Bakker E, Kurz X, et al. Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe. Front Pharmacol. 2022 Aug 4;13:924648. PMID: 35991868; PMCID: PMC9386590. doi: 10.3389/fphar.2022.924648
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Summary of the risk management plan for vitrakvi. 2019. [cited 2022 19 Jun]; Available from: https://www.ema.europa.eu/en/documents/rmp-summary/vitrakvi-epar-risk-management-plan-summary_en.pdf.
   Google Scholar
• Mercuri E, Muntoni F, Osorio AN, et al. Safety and effectiveness of ataluren: comparison of results from the STRIDE registry and CINRG DMD natural history study. J Comp Eff Res. 2020 Apr;9(5):341–360.
   PubMed Web of Science ®Google Scholar
• Weinreb NJ, Kaplan P. The history and accomplishments of the ICGG Gaucher registry. Am J Hematol. 2015;90(Suppl1):S2–5. doi: 10.1002/ajh.24054
   PubMedGoogle Scholar
• El-Beshlawy A, Tylki-Szymanska A, Vellodi A, et al. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry. Mol Genet Metab. 2017 Jan;120(1–2):47–56.
   PubMed Web of Science ®Google Scholar
• Mistry PK, Batista JL, Andersson HC, et al. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry. Am J Hematol. 2017;92:929–939. doi: 10.1002/ajh.24801
   PubMed Web of Science ®Google Scholar
• Weinreb NJ, Goldblatt J, Villalobos J, et al. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metabol Disease. 2013;36(3):543–553. doi: 10.1007/s10545-012-9528-4
   PubMed Web of Science ®Google Scholar
• Grabowski GA, Zimran A, Ida H. Gaucher disease types 1 and 3: phenotypic characterization of large populations from the ICGG gaucher registry. Am J Hematol. 2015;90(Suppl 1):S12–8. doi: 10.1002/ajh.24063
   PubMed Web of Science ®Google Scholar
• Tylki-Szymanska A, Vellodi A, El-Beshlawy A, et al. Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International collaborative gaucher group neurological outcomes subregistry. J Inherit Metabol Disease. 2010;33(4):339–346. doi: 10.1007/s10545-009-9009-6
   PubMed Web of Science ®Google Scholar
• Wenstrup RJ, Kacena KA, Kaplan P, et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res. 2007;22:119–126. doi: 10.1359/jbmr.061004
   PubMed Web of Science ®Google Scholar
• Cole JA, Taylor JS, Hangartner TN, et al. Reducing selection bias in case-control studies from rare disease registries. Orphanet J Rare Dis. 2011;6(1):61. doi: 10.1186/1750-1172-6-61
   PubMedGoogle Scholar
• Leary R, Oyewole AO, Bushby K, et al. Translational Research in Europe for the Assessment and Treatment for Neuromuscular Disorders (TREAT-NMD). Neuropediatrics. 2017 Aug;48(4):211–220. Epub 2017 Jul 6. PMID: 28683502. doi: 10.1055/s-0037-1604110
   PubMed Web of Science ®Google Scholar
• Jannot AS, Messiaen C, Khatim A, et al. The ongoing French BaMaRa-BNDMR cohort: implementation and deployment of a nationwide information system on rare disease. J Am Med Inform Assoc. 2022 Jan 29;29(3):553–558. doi: 10.1093/jamia/ocab237
   PubMed Web of Science ®Google Scholar
• Batshaw ML, Tuchman M, Summar M, et al. A longitudinal study of urea cycle disorders. Mol Genet Metab. 2014 Sep;113(1–2):127–130.
   PubMed Web of Science ®Google Scholar
• EMA. Initiative for patient registries: strategy and pilot phase. Published in 2015. [cited 2023 19 Jun]; Available from: https://www.ema.europa.eu/en/documents/other/initiative-patient-registries-strategy-pilot-phase_en.pdf.
   Google Scholar
• European Medicines Agency (EMA). Patient registry initiative- strategy and mandate of the cross-committee task force. Published in 2017. [cited 2023 Jun 19]; Available from: https://www.ema.europa.eu/en/documents/other/patient-registry-initiative-strategy-mandate-cross-committee-task-force_en.pdf.
   Google Scholar
• Food and Drug Administration (FDA). Real-world data: assessing registries to support regulatory decision-making for drug and biological products guidance for industry. Published in 2021. [cited 2023 19 Jun]; Available from: https://www.fda.gov/media/154449/download.
   Google Scholar
• International Rare Diseases Research Consortium. Policies & Guidelines. Published in 2013. [cited 2023 Jun 19]; Available from: http://www.irdirc.org/wp-content/uploads/2017/10/IRDiRC_Policies_Longversion_24May2013.pdf.
   Google Scholar
• EURORDIS-NORD-CORD. EURORDIS-NORD-CORD joint declaration of 10 key principles for rare disease patient registries. Published in 2012. [cited 2023 Jun 19]; Available from: http://download2.eurordis.org/documents/pdf/EURORDIS_NORD_CORD_JointDec_Registries_FINAL.pdf.
   Google Scholar
• Héon-Klin V. European reference networks for rare diseases: what is the conceptual framework? Orphanet J Rare Dis. 2017 Aug 7;12(1):137. doi: 10.1186/s13023-017-0676-3
   PubMedGoogle Scholar
• European Commission Joint Research Centre. Set of common data elements for rare diseases registration. [cited 2023 Apr 26]; Available from: https://eu-rd-platform.jrc.ec.europa.eu/sites/default/files/CDS/EU_RD_Platform_CDS_Final.pdf.
   Google Scholar
• Berger A, Rustemeier AK, Göbel J, et al. How to design a registry for undiagnosed patients in the framework of rare disease diagnosis: suggestions on software, data set and coding system. Orphanet J Rare Dis. 2021 May 1;16(1):198. doi: 10.1186/s13023-021-01831-3.
   PubMed Web of Science ®Google Scholar